Results 171 to 180 of about 31,452 (261)
Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors. [PDF]
Front ImmunolPark JA, Cheung NV.
europepmc +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 745-752, September 2026.The minimal anticipated biological effect level (MABEL) approach to first‐in‐human (FIH) dose calculation can lead to long dose‐escalation periods before observing clinical activity. We used a novel ex vivo MABEL approach to calculate the FIH starting dose for forimtamig, a T‐cell bispecific antibody under investigation for the treatment of relapsed ...
Thomas E. Kraft +16 more
wiley +1 more source
Comparison of PSMA/FAPI Bispecific Tracer ¹⁸F-ALF-NOTA-PSFA-1 and ¹⁸F-FDG PET/CT in the Detection of Primary Clear Cell Sarcoma of Bone. [PDF]
Clin Nucl MedWu J, Gao H, He L, Liu N, Zhang W.
europepmc +1 more source
Intelligent design of artificial biocatalyst for biomedical diseases
Journal of Intelligent Medicine, Volume 3, Issue 3, Page 220-249, September 2026.This review summarizes recent advances in the intelligent design of artificial biocatalysts for biomedical diseases. By leveraging tailored design strategies, including environment‐responsive engineering and rational/artificial intelligence‐aided optimization, these biocatalysts enable precise modulation of pathological microenvironments and targeted ...
Lijie Zhang +3 more
wiley +1 more source
A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers. [PDF]
Oncol ResZhao H +5 more
europepmc +1 more source
MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.The image illustrates how PROTACs utilize endocytosis, mediated by cell surface proteins, to overcome bioavailability limitations and enable efficient intracellular delivery. ABSTRACT Proteolysis‐targeting chimeras (PROTACs) are promising therapeutic agents for targeted protein degradation via the ubiquitin‐proteasome system; however, their clinical ...
Huahua Chen +3 more
wiley +1 more source
Abscopal Effect in Radiation Therapy: The Immune Mechanisms and Clinical Advances
MedComm, Volume 7, Issue 9, September 2026.The schematic outlines the key events of the abscopal effect. (Ignition) Local radiotherapy (RT) induces the release of immunogenic signals from the tumor, leading to dendritic cell (DC) activation. (Orchestration) In the tumor‐draining lymph node (TDLN), DCs prime naive T cells into cytotoxic T lymphocytes (CTLs), a process modulated by regulatory T ...
Yihong Dong +5 more
wiley +1 more source
Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico. [PDF]
Antibodies (Basel)Turco G +4 more
europepmc +1 more source
Prostate Cancer Development, Progression, and Therapy
MedComm – Oncology, Volume 5, Issue 3, September 2026.This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin +9 more
wiley +1 more source